Human Immunodeficiency Virus Type 1 gp41 Binds to Candida albicans via Complement C3-like Region

Oral candidiasis in human immunodeficiency virus type 1 (HIV-1)-infected persons is believed to be caused by the acquired T lymphocyte immunodeficiency. The direct interaction of C. albicans and HIV-1 in vitro was investigated. Twice as many yeasts adhered to cells transfected with the HIV-1 env gene as they did to controls. HIV-1 rsgp160 and rsgp41 but not rsgp120 were found to bind to Candida albicans via two C3-like regions within gp41. Normal human serum, but not C3-depleted serum, was able to inhibit rsgp41 binding to C. albicans. Vice versa, rsgp160 and rsgp41 were able to block rosetting of C. albicans with iC3b-coated sheep erythrocytes. Binding to C. albicans, and its inhibition by rsgp41 or rsgp160, was confirmed for the whole virus. Therefore, oral candidiasis in HIV-1-infected subjects may be augmented or may even be initiated by direct interaction between C. albicans and HIV-1 or HIV-1-infected cells.

[1]  T. Kupper,et al.  HIV-infected Langerhans cells constitute a significant proportion of the epidermal Langerhans cell population throughout the course of HIV disease. , 1996, The Journal of investigative dermatology.

[2]  M. Dierich,et al.  The human immunodeficiency virus type 1 transmembrane gp41 protein is a calcium-binding protein and interacts with the putative second-receptor molecules in a calcium-dependent manner. , 1996, Journal of virology.

[3]  M. McClellan,et al.  Cloning and expression of a gene encoding an integrin-like protein in Candida albicans. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Dierich,et al.  Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55) , 1996, The Journal of experimental medicine.

[5]  L. Lopalco,et al.  HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology. , 1995, AIDS research and human retroviruses.

[6]  M. Dierich,et al.  Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1. , 1995, Immunobiology.

[7]  M. Dierich,et al.  Interaction of several complement proteins with gp120 and gp41, the two envelope gycoproteins of HIV‐1 , 1995, AIDS.

[8]  A. Trkola,et al.  A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. , 1994, AIDS research and human retroviruses.

[9]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Ballaun,et al.  Epidermal langerhans cells of AIDS patients express HIV-1 regulatory and structural genes. , 1994, The Journal of investigative dermatology.

[11]  D. Phillips,et al.  The role of cell-to-cell transmission in HIV infection. , 1994, AIDS.

[12]  J. Möst,et al.  Ca ions stabilize the binding of complement factor iC3b to the pseudohyphal form of Candida albicans , 1994, Infection and immunity.

[13]  N. Thielens,et al.  HIV and human complement: mechanisms of interaction and biological implication. , 1993, Immunology today.

[14]  R. Calderone,et al.  Isolation of avirulent clones of Candida albicans with reduced ability to recognize the CR2 ligand C3d , 1993, Infection and immunity.

[15]  M. Dierich,et al.  Isolation and biochemical characterization of the iC3b receptor of Candida albicans , 1993, Infection and immunity.

[16]  H. Masur,et al.  Esophageal disease in AIDS is associated with pathologic processes rather than mucosal human immunodeficiency virus type 1. , 1993, The Journal of infectious diseases.

[17]  S. M. Stearns,et al.  Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity , 1992, Journal of virology.

[18]  S E Macatonia,et al.  Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. , 1990, Immunology.

[19]  M. Ollert,et al.  Reduced expression of the functionally active complement receptor for iC3b but not for C3d on an avirulent mutant of Candida albicans , 1990, Infection and immunity.

[20]  B. Moss,et al.  Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. , 1989, AIDS research and human retroviruses.

[21]  T. Schulz,et al.  C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3 , 1989, Infection and immunity.

[22]  J. Lambris,et al.  A 34-amino acid peptide of the third component of complement mediates properdin binding. , 1988, Journal of immunology.

[23]  M. Dierich,et al.  Candida albicans and Candida stellatoidea, in contrast to other Candida species, bind iC3b and C3d but not C3b , 1985, Infection and immunity.

[24]  G. Fey,et al.  Human complement component C3: cDNA coding sequence and derived primary structure. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Mark L. Pearson,et al.  Complete nucleotide sequence of the AIDS virus, HTLV-III , 1985, Nature.

[26]  G. Friedland,et al.  Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. , 1984, The New England journal of medicine.

[27]  D. Fearon,et al.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase , 1975, The Journal of experimental medicine.

[28]  M. Dierich,et al.  Temperature-dependent surface expression of the beta-2-integrin analogue of Candida albicans and its role in adhesion to the human endothelium. , 1996, Experimental and clinical immunogenetics.

[29]  M. Hostetter,et al.  An iC3b receptor on Candida albicans: structure, function, and correlates for pathogenicity. , 1988, The Journal of infectious diseases.

[30]  J. Janatova.  C3, C5 components and C3a, C4a, and C5a fragments of the complement system. , 1988, Methods in enzymology.

[31]  F. Odds,et al.  Candida and candidosis , 1979 .